Source: Pharmaceutical Business Review

LSP: Tubulis secures $138.8m to develop ADCs for solid tumours

EQT Life Sciences and Nextech Invest jointly led the financing round with contributions from new US-based investors, Frazier Life Sciences and Deep Track Capital. Existing investors including Andera The post Tubulis secures $138.8m to develop ADCs for solid tumours appeared first on Pharmaceutical Business review.

Read full article »
LSP's Competitors | LSP's News | LSP's Financials
Stay up-to-date with the latest news on LSP
Est. Annual Revenue
$25-100M
Est. Employees
25-100
Martijn Kleijwegt's photo - Managing Partner of LSP

Managing Partner

Martijn Kleijwegt

CEO Approval Rating

69/100

Read more
Stay up-to-date with the latest news on LSP